$IRD

Magrath George sold $28K of IRD

Magrath George (Chief Executive Officer) sold 9,475 shares of Opus Genetics, Inc. (IRD) at $2.95 on 2026-07-23.

Original reporting
SEC EDGAR · Magrath George
Published Jul 27, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 27, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRD
Neutral
medium confidence
Mentioned
$IRD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRDNeutralLow
01

Why it matters

Traders may monitor for clustering of insider sales or follow-on disclosures, but this specific filing does not provide new operational or financial guidance.

02

Market read

A CEO open-market sale of $27.9K is disclosed, which may slightly affect sentiment but is unlikely to drive fundamentals.

03

What to watch

The absence of a stated 10b5-1 plan may raise speculation, but Form 4s can still reflect pre-planned trading or routine compensation-related activity not captured here.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-27 after-hours; reflects sale executed 2026-07-23.

Background

The article is an SEC Form 4 insider transaction disclosure for Opus Genetics, Inc.

Company-level read

Ticker impact

$IRDNeutralMedium confidence
Context

Opus Genetics CEO Magrath George sold 9,475 shares on 2026-07-23 at $2.9473, totaling $27,925.67, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no earnings, guidance, deal, or operational update. Insider sales can be non-informational, and the disclosed value is relatively small.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs, especially given the small dollar amount and lack of any accompanying negative corporate event.

Key entities

  • Opus Genetics, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Magrath George

    CEO and officer/director who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRDMedAI 8/10

Opus Genetics receives FDA clearance for RDH12-LCA gene therapy

Opus Genetics (NASDAQ:IRD) received FDA clearance for its gene therapy OPGx-RDH12, targeting RDH12-associated Leber congenital amaurosis. The company plans to start a Phase 1/2 trial this quarter. The therapy aims to restore retinal function in a rare inherited disease affecting 30,900 people globally. Opus Genetics collaborates with the Global RDH12 Alliance, which committed up to $1.6 million for development.

$IRDMedAI 8/10

Opus Genetics (IRD) Gains FDA Approval for Ryzumvi Label Expansi

Opus Genetics (IRD) received FDA approval to expand Ryzumvi's use to adults with presbyopia, a milestone that triggers a payment from partner Viatris (VTRS). IRD's P/S ratio is 29.84, far above its historical median, reflecting high growth expectations despite its unprofitability. The company's GF Score is 21, indicating financial and operational challenges, and insiders have sold $19.3M in shares over the past year.

$IRDMedAI 9/10

Opus Genetics (IRD) Gains FDA Approval for Phentolamine Ophthalm

Opus Genetics (IRD) received FDA approval for its phentolamine ophthalmic solution, triggering a licensing agreement payment. The company trades at a high P/S ratio of 30.33, reflecting growth expectations despite financial challenges. Insider activity shows significant selling. The FDA approval follows successful clinical trials for presbyopia treatment.

$IRDHighAI 8/10

FDA approves Opus Genetics’ eye drops for presbyopia treatment

Opus Genetics (IRD) received FDA approval for RYZUMVI, a drug to treat presbyopia in adults. The approval expands the drug's use beyond its initial indication. The company has a licensing agreement with Viatris (VTRS), which holds U.S. commercialization rights. The FDA approval triggers a milestone payment to Opus Genetics, though the amount was not disclosed.